<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579032</url>
  </required_header>
  <id_info>
    <org_study_id>ML2863</org_study_id>
    <nct_id>NCT01579032</nct_id>
  </id_info>
  <brief_title>Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.</brief_title>
  <official_title>Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the presented study are as follows:&#xD;
&#xD;
        1. To evaluate the endothelial function and arterial stiffness in a large cohort of&#xD;
           prevalent CKD patients by means of non-invasive applantion tonometry.&#xD;
&#xD;
        2. To evaluate the association between the serum levels of the representatives of the&#xD;
           various classes of uremic toxins and markers of endothelial function and arterial&#xD;
           stiffness.&#xD;
&#xD;
        3. To evaluate the association between markers of inflammation and oxidative stress and&#xD;
           markers of endothelial function and arterial stiffness.&#xD;
&#xD;
        4. To evaluate the association between echocardiographic parameters and markers of arterial&#xD;
           stiffness&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Arterial Stiffness</condition>
  <condition>CHRONIC RENAL FAILURE</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>CKD patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        CKD patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-60&#xD;
&#xD;
          -  Chronic kidney disease: according to the K-DOQI guidelines ( kidney damage ≥ three&#xD;
             months, as defined by structural or functional abnormalities of the kidney, with or&#xD;
             without decreased GFR, manifest by either: pathological abnormalities; or markers of&#xD;
             kidney damage, including damage in the composition of blood or urine test, or&#xD;
             abnormalities in imaging tests; GFR&lt; 60 ml/min/1.73m² for ≥ three months, with or&#xD;
             without kidney damage)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  major illnesses( life expectancy of &lt; 1 year)&#xD;
&#xD;
          -  history of atrial fibrillation&#xD;
&#xD;
          -  history of myocardial infarction, unstable angina, congestive heart failure,&#xD;
             peripheral vascular diasease ,cerebrovascular disease, diabetes&#xD;
&#xD;
        (nonechogenic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

